Close Menu

BG Medicine

In an amended preliminary prospectus for its IPO filed this week, the company noted that it plans to apply more than half the funds raised by the offering to the development of its BGM Galectin-3, AMIPredict, and LipidDx protein biomarker products.

The firm aims to go public at a price of between $13 and $15 per share. It plans to use proceeds to fund the commercial launch of the BGM Galectin-3 test, as well as development of other tests.

BG has filed for an IPO in the US, a few years after withdrawing an effort to float on the Euronext Amsterdam Exchange.

The offering, which would be the company's second try at going public in the past two and a half years, would raise as much as $86 million.

The collaboration is the first cooperative research-and-development agreement between FHS and a commercial partner in the study's 60-year history. It also marks the first time the study has ever used proteomics.


Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.